- Open
- 14310.00
- High
- 14310.00
- Low
- 13948.00
- Close
- 13961.48
- Change
- -532.00 (-3.67%)
- Volume
- 1,388,649
⌘K
| 27 Apr 2026 | 07:00:10 | Saphnelo self-administration approved in the US |
| 23 Apr 2026 | 07:00:06 | Directorate change |
| 21 Apr 2026 | 07:00:08 | I CAN PhIII interim analysis met primary endpoint |
| 20 Apr 2026 | 07:00:07 | Third tozorakimab positive Phase III in COPD |
| 9 Apr 2026 | 17:15:01 | Result of AGM |
| 24 Feb 2026 | 2025 Annul Report & 20-F Information | |
| 18 Feb 2025 | 2024 Annual Report & 20-F Information | |
| 20 Feb 2024 | AstraZeneca PLC Annual Report & 20-F Information 2023 |
We are a multinational pharmaceutical corporation with a significant presence in the United Kingdom. Our mission is to advance scientific frontiers and provide transformative medications that improve lives.
Lord Goldsmith and 5 other people have interests in this issuer
| 27 Apr 2026 | 07:00:10 | Saphnelo self-administration approved in the US |
| 23 Apr 2026 | 07:00:06 | Directorate change |
| 21 Apr 2026 | 07:00:08 | I CAN PhIII interim analysis met primary endpoint |
| 20 Apr 2026 | 07:00:07 | Third tozorakimab positive Phase III in COPD |
| 9 Apr 2026 | 17:15:01 | Result of AGM |
| 24 Feb 2026 | 2025 Annul Report & 20-F Information | |
| 18 Feb 2025 | 2024 Annual Report & 20-F Information | |
| 20 Feb 2024 | AstraZeneca PLC Annual Report & 20-F Information 2023 |
We are a multinational pharmaceutical corporation with a significant presence in the United Kingdom. Our mission is to advance scientific frontiers and provide transformative medications that improve lives.
Lord Goldsmith and 5 other people have interests in this issuer